ESR2 and breast cancer: One likely explanation for our findings in BC is that all of the previous studies that have measured ER-β in BC have focused on response to tamoxifen therapy in either adjuvant or metastatic settings [26,31], while our subset of node-positive BC patients mostly received adjuvant CHT (with or without ACs).